Allogene Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
ALLO$1.06+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share amounts)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $29,270 | $51,688 |
| Short-term investments | 263,688 | 198,522 |
| Prepaid expenses and other current assets | 6,868 | 7,539 |
| Total current assets | 299,826 | 257,749 |
| Long-term investments | 95,915 | 8,043 |
| Operating lease right-of-use asset | 36,642 | 39,888 |
| Property and equipment, net | 64,821 | 72,839 |
| Deposit placed in escrow | — | 23,479 |
| Restricted cash | 10,292 | 10,292 |
| Other long-term assets | 3,824 | 3,615 |
| Total assets | $511,320 | $415,905 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $8,775 | $4,270 |
| Accrued and other current liabilities | 29,723 | 28,244 |
| Total current liabilities | 38,498 | 32,514 |
| Lease liability, noncurrent | 68,039 | 75,045 |
| Other long-term liabilities | 12,231 | 15,804 |
| Total liabilities | 118,768 | 123,363 |
| Commitments and Contingencies (Notes 6 and 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value: 10,000,000 shares authorized as of September 30, 2026 and December 31, 2025; no shares were issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value: 800,000,000 and 400,000,000 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 346,279,825 and 229,413,523 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 346 | 229 |
| Additional paid-in capital | 2,540,011 | 2,302,753 |
| Accumulated deficit | (2,146,362) | (2,010,709) |
| Accumulated other comprehensive income (loss) | (1,443) | 269 |
| Total stockholders’ equity | 392,552 | 292,542 |
| Total liabilities and stockholders’ equity | $511,320 | $415,905 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.